Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

Added 278 days ago (20.12.2020)
Authors: Sara Rundquist, Michael C. Sachs, Carl Eriksson, Ola Olén, Scott Montgomery, Jonas Halfvarson, The SWIBREG Study Group, Marie Andersson, Jonas Bengtsson, Jan Björk, Michael Eberhardson, Ulrika L. Fagerberg, Olof Grip, Henrik Hjortswang, Susanna Jäghult, Pontus Karling, Jonas F. Ludvigsson, Pär Myrelid, Caroline Nordenvall, Malin Olsson, Martin Rejler, Hans Strid
Read article